Cancer/testis (CT) antigens: potential targets for immunotherapy.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuMAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinomaRNA vaccines in cancer treatmentMageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBsIntronic promoter drives the BORIS-regulated expression of FerT in colon carcinoma cellsExpression of evolutionarily novel genes in tumorsMHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cellsT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesDNA vaccine for cancer immunotherapyImmunotherapy for Bone and Soft Tissue SarcomasCancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancerA novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancerSperm associated antigen 9 plays an important role in bladder transitional cell carcinomaThe blood-testis barrier and its implications for male contraceptionEquitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptomeDifferential expression of PRAMEL1, a cancer/testis antigen, during spermatogenesis in the mouseTumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes.Retrotransposon hypomethylation in melanoma and expression of a placenta-specific geneTumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.The prevalence and expression pattern of melanoma-associated antigen 1 in esophageal squamous cell carcinoma: a historical cohort studySerum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma.Frequent MAGE mutations in human melanomaNY-ESO-1 expression in DCIS: A new predictor of good prognosis.Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomasDNA vaccines: developing new strategies against cancer.High expression and frequently humoral immune response of melanoma-associated antigen D4 in gliomaMultiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expressionRegulation of spermiogenesis, spermiation and blood-testis barrier dynamics: novel insights from studies on Eps8 and Arp3.Evolutionary history of the cancer immunity antigen MAGE gene family.Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines.High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesNY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancerOverexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target
P2860
Q21131200-9A6FDE3C-964E-4B27-85C8-A565AE7939B9Q21134039-84EC4438-3AF2-4CD9-A6D9-9B105242B4E2Q21296852-8E9B56D4-0D52-4ED3-A9AA-862D7093C903Q24298306-C70ACBFD-BE65-46D7-8BA5-90F0D5E7C2DAQ24301079-1892D9D9-5FEE-4B58-B11F-1B4C737C9BA2Q26738894-252A6596-7C14-47FF-B4FD-B72A5B541BC1Q26866479-26504769-F196-4D19-A7F3-8637A4E1D293Q28074619-D13DF65E-0685-4254-A4E1-83B23F0BA24FQ28080919-9C8E8357-9095-400E-94F4-DBD9DA6A60AAQ28088363-75CF42A2-968B-46F9-B126-A1A0657606ADQ28273809-A7D56F7D-8B8D-4665-929B-E28B104660A1Q28274654-ECCB649E-AA88-45C8-BDCE-CD2174CC239EQ28304265-822D16EB-ABDA-47D1-9D61-FB90BEFE1AFFQ28395237-433535D8-722D-41CA-A4A6-7562787AE278Q28475641-C4D394ED-C8C1-4864-9739-9F5A7EA3BE11Q28587770-13AC3A8C-6E6C-4A75-B707-A6AADDC60DB3Q29616128-7960FF61-6809-4D91-9665-2641E292A1A9Q30558949-84BE89C7-C301-4A79-981F-4F7457EDC36CQ31159345-67DFE3CE-F1B0-4D93-B5C3-7BDE31119B02Q33555751-A5AC1CF3-4090-4DBC-9903-DB09E26CBA3EQ33588711-CFFDBF30-711B-4D98-8362-7E0494E235CAQ33599094-67F21138-C741-40FA-BBE5-01F041BCA2E0Q33620367-6B66441E-E099-4C1D-B8BE-3DED6E7B4592Q33686433-60E60B36-24C0-4FC4-A976-4A6CC788A738Q33700477-7BDD43B3-95B0-4B4C-AFAB-CE071B78B69FQ33718676-F4B51EE2-791D-4B2C-930B-2B46D57508F0Q33734053-E96A09AD-86D1-4B16-892E-44C23BBC1BE0Q33756622-9F4FC721-4A32-40DF-AEBA-DECEFD209440Q33802891-7B71B85D-FCAA-4381-89FD-9C889223F6BAQ33855568-E0A00AC9-57AD-4D0C-B096-E29A1BA3D79DQ33931434-ABC9E8AD-0E29-43AF-A5E6-593B1F398D03Q33939395-EF00B324-94A0-4E1C-A796-64DFCA0575E3Q33939709-4F679B72-2AE4-4D90-814F-1216AF97244EQ33941999-1B3ABD27-0786-4AE3-98FC-1C94E2725ECBQ33963953-E8E70055-6046-463B-A515-EFE76778C852Q33980682-B4A8F51C-F82C-40A7-A68E-700C9DDDB803Q33987977-64D1A1C2-01D6-4160-BAEC-E42538D8F9E3Q33994533-B5B91CB2-0946-4DA3-938F-E287C2CC6F5EQ34015590-C100E893-AED2-4536-9501-5B9F003440F4Q34029028-BE6375C0-AE52-488A-A4C8-97F867EE869D
P2860
Cancer/testis (CT) antigens: potential targets for immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cancer/testis (CT) antigens: potential targets for immunotherapy.
@en
Cancer/testis
@nl
type
label
Cancer/testis (CT) antigens: potential targets for immunotherapy.
@en
Cancer/testis
@nl
prefLabel
Cancer/testis (CT) antigens: potential targets for immunotherapy.
@en
Cancer/testis
@nl
P2860
P1433
P1476
Cancer/testis (CT) antigens: potential targets for immunotherapy.
@en
P2093
Otavia L Caballero
Yao-Tseng Chen
P2860
P304
P356
10.1111/J.1349-7006.2009.01303.X
P577
2009-08-01T00:00:00Z